Details were thin, but Syntopix Group (AIM: SYN), the speciality pharmaceutical research and development company focused on tropical treatment of dermatological diseases, announced that it had signed an “exclusive evaluation agreement” with a “major” consumer healthcare company.
Syntopix will supply its library of compounds for evaluation of their application in commercial products. Syntopix did confirm that it would receive an upfront payment at the start of the exclusive period, but did not say how much. No other financial details of the agreement were released.
Dr Stephen Jones, Syntopix' Chief Executive Officer, said:
'I am delighted that Syntopix has entered into this agreement with one of the world's largest consumer healthcare companies. We continue to identify potential markets for to the antimicrobial expertise of Syntopix, and we believe that our technology has the potential to improve the effectiveness of many healthcare brands. Our core focus remains the development of products for the topical treatment of dermatological diseases, though this agreement further highlights our ability to leverage our assets into consumer healthcare'
No comments:
Post a Comment